Bedini A, Codeluppi M, Cocchi S, Guaraldi G, Di Benedetto F, Venturelli C, Masetti M, Prati F, Mussini C, Borghi V, Girardis M, Gerunda G E, Rumpianesi F, Esposito R
Department of Internal Medicine and Medical Specialties, Infectious Diseases Clinic, University of Modena and Reggio Emilia, Policlinico of Modena, Modena, Italy.
Transplant Proc. 2007 Jul-Aug;39(6):1947-9. doi: 10.1016/j.transproceed.2007.05.055.
The objective of the study was to assess the incidence, risk factors, and survival of gram-positive bloodstream infections (GP-BSI(s)) among liver transplant recipients during the first year after transplantation. Between October 2000 and September 2006, 42 episodes of GP-BSI(s) occurred in 205 patients with an overall incidence of 0.20 episodes/patient. Coagulase-negative staphylococci were detected in 45.2% of cases, Enterococcus species in 42.9% (E faecalis, eight; E faecium, seven; E avium, two; E gallinarum, one) and Staphylococcus aureus in 11.9%. Retransplantation was the only independent risk factor for GP-BSI (odds ratio [OR], 0.253; 95% confidence interval (CI), 0.089 to 0.715; P = .009). Thirty-day mortality rate was 28.5% and S aureus infections were related to a poorer outcome. It is noteworthy that all the isolates of S aureus were methicillin-resistant. Ampicillin was inactive against all the strains of E faecium and 50% of E avium isolates, but active against all E faecalis and E gallinarum strains. All the isolates were glycopeptide-susceptible. No significant differences in mortality rate were observed in relation to sex, etiologies of end-stage liver disease, cytomegalovirus infection/reinfection, type of donor, rejection, or retransplantation. GP-BSI, the only independent risk factor for death (OR, 0.262; 95% CI, 0.106 to 0.643; P = .003), reduced the survival rate by 26% in the first year posttransplant. In conclusion, GP-BSI(s) impact significantly on morbidity and mortality posttransplant, particularly among retransplantations. Control measures are required to reduce the incidence of GP-BSI(s) in liver transplant recipients. These findings must be considered when empirical antimicrobial therapy is indicated while awaiting blood-culture results.
本研究的目的是评估肝移植受者在移植后第一年革兰氏阳性血流感染(GP-BSI)的发生率、危险因素及生存率。2000年10月至2006年9月期间,205例患者发生了42次GP-BSI,总发生率为0.20次/患者。45.2%的病例检测到凝固酶阴性葡萄球菌,42.9%为肠球菌属(粪肠球菌8例、屎肠球菌7例、鸟肠球菌2例、鹑鸡肠球菌1例),11.9%为金黄色葡萄球菌。再次移植是GP-BSI的唯一独立危险因素(比值比[OR],0.253;95%置信区间[CI],0.089至0.715;P = 0.009)。30天死亡率为28.5%,金黄色葡萄球菌感染与较差的预后相关。值得注意的是,所有金黄色葡萄球菌分离株均为耐甲氧西林菌株。氨苄西林对所有屎肠球菌菌株及50%的鸟肠球菌分离株无活性,但对所有粪肠球菌和鹑鸡肠球菌菌株有活性。所有分离株对糖肽类敏感。在性别、终末期肝病病因、巨细胞病毒感染/再感染、供体类型、排斥反应或再次移植方面,未观察到死亡率有显著差异。GP-BSI是死亡的唯一独立危险因素(OR,0.262;95% CI,0.106至0.643;P = 0.003),在移植后第一年使生存率降低了26%。总之,GP-BSI对移植后的发病率和死亡率有显著影响,尤其是在再次移植患者中。需要采取控制措施以降低肝移植受者中GP-BSI的发生率。在等待血培养结果并进行经验性抗菌治疗时,必须考虑这些发现。